All Stories

  1. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

    Article • Journal of Translational Medicine, November 2017, Springer Science + Business Media

    Professor Giuseppe V Masucci

  2. Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome

    Article • Translational Research, August 2015, Elsevier

    Professor Giuseppe V Masucci

  3. Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation

    Article • Journal of Translational Medicine, January 2015, Springer Science + Business Media

    Professor Giuseppe V Masucci

  4. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

    Article • Journal of Translational Medicine, October 2014, Springer Science + Business Media

    Professor Giuseppe V Masucci

  5. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma

    Article • Cancer Immunology Immunotherapy, July 2014, Springer Science + Business Media

    Professor Giuseppe V Masucci

  6. Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy

    Article • Cancer Immunology Immunotherapy, June 2014, Springer Science + Business Media

    Professor Giuseppe V Masucci

  7. A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA

    Article • Modern Pathology, February 2014, Nature

    Professor Giuseppe V Masucci

  8. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

    Article • The Journal of Pathology, December 2013, Wiley

    Professor Giuseppe V Masucci

  9. Genotyping of Human Leukocyte Antigen (HLA) Ancestral Haplotypes as Prognostic Marker in Cancer Using PCR Analysis

    Article • October 2013, Springer Science + Business Media

    Professor Giuseppe V Masucci

  10. HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome

    Article • PLoS ONE, October 2013, PLOS

    Professor Giuseppe V Masucci

  11. Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production

    Article • Cancer Immunology Research, August 2013, American Association for Cancer Research (AACR)

    Professor Giuseppe V Masucci

  12. Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Professor Giuseppe V Masucci

  13. HLA-dependent tumour development: a role for tumour associate macrophages?

    Article • Journal of Translational Medicine, January 2013, Springer Science + Business Media

    Professor Giuseppe V Masucci

  14. Cancer classification using the Immunoscore: a worldwide task force

    Article • Journal of Translational Medicine, October 2012, Springer Science + Business Media

    Professor Giuseppe V Masucci

  15. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer

    Article • Cancer Immunology Immunotherapy, January 2012, Springer Science + Business Media

    Professor Giuseppe V Masucci

  16. Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours

    Article • Journal of Translational Medicine, January 2012, Springer Science + Business Media

    Professor Giuseppe V Masucci

  17. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines

    Article • Cancer Immunology Immunotherapy, November 2011, Springer Science + Business Media

    Professor Giuseppe V Masucci

  18. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

    Article • Clinical Cancer Research, May 2011, American Association for Cancer Research (AACR)

    Professor Giuseppe V Masucci

  19. Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas

    Article • Pharmaceutical Statistics, October 2010, Wiley

    Professor Giuseppe V Masucci, Professor Dario Gregori

  20. Immature Immunosuppressive CD14+HLA-DR-/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

    Article • Cancer Research, May 2010, American Association for Cancer Research (AACR)

    Professor Giuseppe V Masucci

  21. A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins

    Article • Cancer Research, March 2010, American Association for Cancer Research (AACR)

    Professor Giuseppe V Masucci

  22. The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma

    Article • Cancer Immunology Immunotherapy, February 2009, Springer Science + Business Media

    Professor Giuseppe V Masucci

  23. Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

    Article • Journal of Translational Medicine, January 2009, Springer Science + Business Media

    Professor Giuseppe V Masucci

  24. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma

    Article • Cancer Immunology Immunotherapy, November 2008, Springer Science + Business Media

    Professor Giuseppe V Masucci

  25. A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

    Article • Journal of Translational Medicine, January 2008, Springer Science + Business Media

    Professor Giuseppe V Masucci

  26. Analysis of HLA class I?II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer

    Article • Tissue Antigens, September 2007, Wiley

    Professor Giuseppe V Masucci

  27. A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients

    Article • Cancer Immunology Immunotherapy, December 2006, Springer Science + Business Media

    Professor Giuseppe V Masucci

  28. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer

    Article • Gynecologic Oncology, October 2006, Elsevier

    Professor Giuseppe V Masucci

  29. Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity

    Article • Cancer Research, June 2006, American Association for Cancer Research (AACR)

    Professor Giuseppe V Masucci

  30. Effects of human plasma proteins on maturation of monocyte-derived dendritic cells

    Article • Immunology Letters, September 2005, Elsevier

    Professor Giuseppe V Masucci

  31. Development of a technology platform for large-scale clinical grade production of DC

    Article • Cytotherapy, August 2004, Elsevier

    Professor Giuseppe V Masucci

  32. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer

    Article • British Journal of Cancer, July 2004, Nature

    Professor Giuseppe V Masucci